Detalles de la búsqueda
1.
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Lancet;
402(10395): 41-53, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37331369
2.
Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI.
Radiology;
308(1): e222612, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37462494
3.
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Lancet;
398(10308): 1344-1357, 2021 10 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34555333
4.
Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
Acta Oncol;
61(1): 52-57, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34736367
5.
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Lancet Oncol;
22(7): 931-945, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34051178
6.
Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
Int J Cancer;
149(7): 1463-1472, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34109630
7.
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
N Engl J Med;
379(21): 2040-2051, 2018 11 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30280635
8.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
N Engl J Med;
375(19): 1823-1833, 2016 11 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27718847
9.
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol;
19(1): 87-100, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29223745
10.
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Lancet Oncol;
18(12): 1600-1609, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29129441
11.
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer.
Eur J Cancer;
202: 114007, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38518534
12.
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
Eur Urol;
85(3): 229-238, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37778952
13.
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782.
Lung Cancer;
190: 107506, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38422883
14.
Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
Lancet Gastroenterol Hepatol;
8(2): 133-144, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36470291
15.
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
J Thorac Oncol;
2023 Dec 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38159809
16.
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.
Clin Cancer Res;
29(20): 4166-4177, 2023 Oct 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37490393
17.
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
JTO Clin Res Rep;
4(11): 100572, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37954964
18.
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.
JAMA Oncol;
8(4): 546-552, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35142815
19.
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
Eur J Cancer;
168: 12-24, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35429901
20.
Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience.
Pathol Oncol Res;
27: 1609785, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34257621